Long-term impact of teriparatide on bone mineral density, trabecular bone score, and fracture risk relative to total hip T-score: A two-decade, registry-based cohort study
Teriparatide led to sustained lower incidences of vertebral, hip, and other fractures for up to 8 years after switching to antiresorptive agents in both pretreated and treatment-naïve patients. Additionally, BMD and TBS levels were significantly higher than those before teriparatide treatment. During teriparatide treatment, the total hip T-score did not correlate with fracture risk.
Authors
- Sven Oser (ORCID: https://orcid.org/0000-0002-3487-6444)
- Gernot Schmid (ORCID: https://orcid.org/0000-0002-3435-6844)
- Ueli Studer
- Stephan Reichenbach (ORCID: https://orcid.org/0000-0001-8098-6567)
- Thomas Lehmann (ORCID: https://orcid.org/0000-0003-0739-5562)
- Christian Steiner
- Judith Everts‐Graber (ORCID: https://orcid.org/0000-0002-8792-8199)
- Mathias Wenger
- Oliver Lehmann
- Laura Guyer
- HansJörg Häuselmann
- Hans‐Rudolf Ziswiler
Institutions
- University of Bern (CH)
- University of Lucerne (CH)
- University Hospital of Bern (CH)
- ETH Zurich (CH)
- Federal Roads Office (CH)
- Hirslanden Klinik Im Park (CH)
Publication Details
- Journal
- Bone
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1016/j.bone.2025.117445
- Citations
- 2
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 3.44